Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing https://nevetgbf849709.blogs100.com/37578130/vikings-and-eli-partners-with-usa-tirzepatide-firm-for-global-glp-1-peptides-supply-chain